^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Cancer

    Related cancers:
    1d
    Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (clinicaltrials.gov)
    P2, N=54, Completed, Hospices Civils de Lyon | Unknown status --> Completed | Trial completion date: Oct 2023 --> Jun 2026 | Trial primary completion date: Oct 2023 --> Jun 2026
    Trial completion • Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • ipatasertib (RG7440)
    1d
    Screening of Demethylation-related Biomarkers and Exploration of Regulatory Mechanisms in Esophageal Cancer Patients Based on Machine Learning and Mendelian Randomization. (PubMed, Curr Cancer Drug Targets)
    Six prognostic genes, particularly RAB25 and PLAU, influence ESCC progression and immune microenvironment remodeling.
    Journal
    |
    SERPINH1 (Serpin family H member 1) • MAGEA4 (Melanoma antigen family A, 4) • ANO1 (Anoctamin 1) • COL2A1 (Collagen Type II Alpha 1 Chain) • PLAU (Plasminogen Activator) • RAB25 (RAB25, Member RAS Oncogene Family)
    |
    cisplatin • docetaxel • vinorelbine tartrate
    1d
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=96, Recruiting, Tang-Du Hospital | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    capecitabine • oxaliplatin • Hetronifly (serplulimab)
    1d
    Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=52, Recruiting, Qilu Hospital of Shandong University
    New trial • HEOR
    2d
    A Rare Case of Esophageal Small-Cell Neuroendocrine Carcinoma Presenting With Progressive Dysphagia. (PubMed, Cureus)
    A multidisciplinary approach enabled timely diagnosis and treatment planning. This case highlights the importance of maintaining a broad differential diagnosis and the value of EUS as an essential tool for accurate staging and management of rare esophageal tumors.
    Journal
    |
    SYP (Synaptophysin)
    2d
    E2F4 Mediates Mitophagy to Inhibit Ferroptosis in Esophageal Cancer Cells by Activating GPR176. (PubMed, Hum Mutat)
    Rescue experiments further validated that GPR176 overexpression abrogated the enhanced mitophagy and ferroptosis induced by E2F4 depletion. Collectively, our findings define an E2F4/GPR176/mitophagy axis that acts to suppress ferroptosis in EC, highlighting this pathway as a novel therapeutic target for inducing ferroptosis in EC intervention.
    Journal
    |
    GPR176 (G Protein-Coupled Receptor 176) • PR176 (G Protein-Coupled Receptor 176)
    2d
    Integrative Transcriptomic and Single-Cell Analyses Identify ATP1A1 as a Prognostic and Immune-Associated Factor in Esophageal Cancer. (PubMed, Int J Genomics)
    Experimental validation further showed that ATP1A1 knockdown altered tumor cell behavior and increased inflammatory gene expression in esophageal cancer cells. ATP1A1 represents a prognostically relevant factor linked to tumor biological characteristics, immune microenvironment features, and therapeutic response heterogeneity in esophageal cancer.
    Journal
    |
    ATP1A1 (ATPase Na+/K+ Transporting Subunit Alpha 1)
    2d
    IL15-TransDC: First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients (clinicaltrials.gov)
    P1/2, N=10, Completed, University Hospital, Antwerp | Active, not recruiting --> Completed
    Trial completion • First-in-human
    |
    IL15 (Interleukin 15)
    2d
    HYROC: Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
    New P2 trial
    |
    carboplatin • paclitaxel
    3d
    pH-responsive CDs-based nanoplatform for chemo-resistant esophageal cancer treatment via downregulation of HIF-1α related pathway. (PubMed, J Nanobiotechnology)
    To address this, a pH-responsive nanoplatform, CDs-DOX-GOX@PEG (CDG@PEG), composed of iron-doped carbon dots (Fe-CDs), doxorubicin (DOX), glucose oxidase (GOX), and polyethylene glycol (PEG), was fabricated to improve CREC treatment through synergistic and targeted therapy...Mechanistically, CDG@PEG realized the CREC therapy by down-regulating drug-resistant genes (such as HIF-1α related genes), inducing mitochondrial dysfunction, and triggering cell apoptosis. This work opened new avenues for developing novel therapeutic strategies against chemotherapy-resistant cancers.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    doxorubicin hydrochloride
    4d
    EGFL6 predicts unfavorable prognosis and serves as a potential indicator in esophageal carcinoma. (PubMed, Discov Oncol)
    EGFL6 is significantly upregulated in ESCA and is related to various clinical factors, immune modulation and reduced prognosis. EGFL6 could be identified as a novel prognostic biomarker and a viable therapeutic target for the development of personalized treatment approaches in ESCA.
    Journal
    |
    EGF (Epidermal growth factor)
    4d
    Identification of macrophage polarization-related genes for esophageal cancer risk: a multi-omics Mendelian randomization analysis. (PubMed, Clin Epigenetics)
    We identified LEP, INPP5D, PGF, SPP1, and USP18 as key MP-related genes associated with EC risk, providing potential therapeutic targets for EC.
    Journal
    |
    SPP1 (Secreted Phosphoprotein 1) • INPP5D (Inositol Polyphosphate-5-Phosphatase D) • USP18 (Ubiquitin Specific Peptidase 18)